Start with the formulation

CJC-1295 is a synthetic version of growth-hormone-releasing hormone, or GHRH. It signals the pituitary gland to release growth hormone. The long-acting version has an added drug affinity complex, usually shortened to DAC, which binds to albumin in the blood. That modification was developed to keep the signal active for longer.[8]

The name needs care. CJC-1295 with DAC and preparations described as CJC-1295 without DAC are different active molecules. FDA evaluated them separately, along with their salt forms. A study of one formulation does not establish the effects of another.[6]

This matters whenever someone quotes a week-long half-life. That finding comes from the DAC compound used in the human studies below. It cannot be carried over to a no-DAC product or an unspecified blend.

What changed in the human studies?

A 2006 paper reported two randomized, placebo-controlled studies in healthy adults, lasting 28 and 49 days. CJC-1295 was injected under the skin. After a single injection, average GH concentrations rose two to ten times and remained elevated for at least six days. IGF-1, a hormone influenced by GH, rose about 1.5 to three times for nine to eleven days. The estimated half-life was 5.8 to 8.1 days.[1]

These are meaningful pharmacology findings: the compound reached its target and had a sustained effect. The studies did not demonstrate better sleep, stronger muscles, faster injury recovery or longer life. A higher hormone measurement is an intermediate result, not a measurement of those benefits.

A separate small study sampled blood overnight before treatment and one week after a single injection. GH pulses continued, with no significant change in their frequency or size. However, GH between pulses rose 7.5-fold, while average GH and IGF-1 also increased. The result supports preserved pulsatility alongside a higher baseline. It does not show that treatment recreated a younger person's normal hormone pattern.[2]

A 2009 analysis examined serum protein changes in eleven men and identified possible biomarkers of GH or IGF-1 activity. It was exploratory laboratory work using human samples, not a trial showing improved health or function.[3]

What about growth and body composition?

In mice bred without the GHRH gene, daily CJC-1295 treatment supported normal growth and body composition. Less frequent treatment improved some measures without fully normalizing growth. This is useful evidence in a specific deficiency model, but it does not establish fat loss or muscle gain in adults whose hormone system is intact.[4]

A phase 2 study did investigate CJC-1295 in people with HIV-associated visceral obesity. Its ClinicalTrials.gov record is marked terminated, with no results posted. The old enrollment field should not be treated as a verified count of treated participants.[5]

FDA's review also describes a reported death following a heart attack during that development program. Its account relies on contemporary reports rather than published trial results. Those limited details do not establish whether CJC-1295 caused the event, but they make a blanket reassurance about the program's safety inappropriate.[6]

What do we know about adverse effects?

The short randomized studies reported no serious adverse reactions. That is reassuring within their limited exposure and follow-up.[1] It does not mean participants had no side effects. FDA's review describes injection-site reactions, headaches, diarrhea and flushing, sometimes with transient low blood pressure. The separate pulse study also reported increased heart rate. Long-term safety remains unresolved.[6]

A sustained effect also means that changing the next injection does not immediately remove the previous exposure. Any proposed use needs a clear account of the exact compound, the health problem being addressed and how meaningful benefit and unwanted effects would be assessed.

Why is ipamorelin discussed alongside it?

Ipamorelin stimulates GH release through the ghrelin receptor, rather than the GHRH receptor. That provides a reason to investigate combinations. It does not establish the performance of a particular blend.

In the primary-source search for this review, we did not identify a controlled human trial demonstrating that CJC-1295 plus ipamorelin improves recovery, sleep or body composition. Findings from the individual compounds cannot supply that missing comparison. The DAC distinction still matters when the compounds are combined.

How the evidence fits together

Hormone response

Short human studies support sustained GH and IGF-1 increases with the DAC compound.

Animal outcomes

Growth improved in GHRH-deficient mice. That model differs from typical adult use.

Patient outcomes

The HIV-associated visceral-obesity trial was terminated and has no posted results.

Combination evidence

The reviewed human evidence does not establish the benefits of a CJC-1295/ipamorelin blend.

Approval and the October 2026 policy

CJC-1295 is not an FDA-approved drug.[6] It is also absent from the six-substance list in the October 2026 HHS peptide compounding policy. That document describes conditional enforcement discretion, not drug approval, and should not be presented as permission covering every peptide.[7]

A prescription, a certificate of analysis and a pharmacy's licence answer different questions. None alone establishes that the exact preparation has demonstrated clinical benefit. Access requirements need to be checked for the product and jurisdiction involved.

Questions worth bringing to a clinician

The treatment goal

  • What finding or diagnosis are we trying to address?
  • How would we measure an improvement that matters to me?
  • Which established options fit that goal?

The exact product

  • Does it contain DAC, and which salt or formulation is supplied?
  • Does the cited study use the same preparation and route?
  • If it is a blend, what evidence tests the blend itself?

The follow-up

  • How does my medical history affect the assessment?
  • What changes would prompt reassessment or stopping?
  • Who will evaluate symptoms and interpret follow-up tests?

What to take away

CJC-1295 with DAC has a demonstrated, prolonged hormonal effect in short human studies. The practical question is whether that change produces a worthwhile benefit for a particular person, with acceptable risk. The reviewed evidence has not answered that question for recovery, sleep or body composition.

Questions people ask

Is CJC-1295 with DAC the same as CJC-1295 without DAC?

No. DAC is the albumin-binding modification used in the long-acting human studies. A preparation without DAC is a different active molecule. The reported half-life of about six to eight days cannot be applied to a no-DAC preparation.

Does keeping GH pulses mean CJC-1295 is safer than growth hormone?

That has not been established. A small study found that pulses persisted, but GH levels between pulses rose substantially. It did not compare long-term safety or clinical outcomes with growth hormone injections.

Has CJC-1295 plus ipamorelin been shown to improve recovery?

The primary sources reviewed did not establish a recovery benefit from that combination. The compounds act through different receptors, but that rationale does not show that a particular blend works better or is safer than either compound alone.

Did the October 2026 HHS peptide policy approve CJC-1295?

No. CJC-1295 is not FDA-approved and is not one of the six substances listed in that HHS policy. The policy concerns conditional enforcement discretion for specified compounding, not drug approval.

The evidence

Original studies, trial records and regulator documents used for this article. The study labels distinguish measured outcomes from plans and laboratory findings.

Two short randomized trialsProlonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. PubMed 16352683
Human hormone studyPulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. PubMed 17018654
Exploratory biomarkersActivation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. PubMed 19386527
Mouse studyOnce-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. PubMed 16822960
Trial registryA Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. NCT00267527
FDA scientific evaluationCJC-1295-related bulk drug substances: December 4, 2024 PCAC briefing. FDA briefing
HHS interim policyEnforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. HHS policy and appendices
Rat and laboratory studyHuman growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. PubMed 15817669

Sources checked November 9, 2026. This review covers the cited studies and current US regulator documents; it is not an exhaustive review of every jurisdiction.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. CJC-1295 is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.